Last reviewed · How we verify
Metformin and standard exercise
At a glance
| Generic name | Metformin and standard exercise |
|---|---|
| Also known as | GlumetzaTM 500 mg Extended Release |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Focusing on the Menopausal Transition to Improve Mid-Life Women's Health (PHASE2, PHASE3)
- Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy (PHASE3)
- Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes (NA)
- Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients (EARLY_PHASE1)
- Metformin as an Adjunctive Therapy to Catheter Ablation in Atrial Fibrillation (PHASE4)
- Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis (NA)
- Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: